Endo International (ENDP) Stock Price, News & Analysis

Company Overview

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.28 to $0.75
• 52-Week Range: N/A
• Volume: 9,967 shs
• Average Volume: 28.19 million shs
• Market Capitalization: $141 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Endo International Stock Analysis - MarketRank™

Endo International scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Endo International.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -83.33%

Earnings Growth

Earnings for Endo International are expected to decrease by -83.33% in the coming year, from $0.78 to $0.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ENDP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Endo International does not currently pay a dividend.

Dividend Growth

Endo International does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -2.62

Short Interest

There is no current short interest data available for ENDP.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.01

News Coverage This Week

MarketBeat has tracked 9 news articles for Endo International this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Endo International insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Endo International is held by insiders.

Percentage Held by Institutions

80.39% of the stock of Endo International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENDP Stock Analysis - Frequently Asked Questions

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) issued its earnings results on Thursday, November, 4th. The company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.34. The business's revenue for the quarter was up 21.6% compared to the same quarter last year.

What other stocks do shareholders of Endo International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Endo International investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Bank of America (BAC), Micron Technology (MU) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 6/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ENDP
• CIK: 1593034
• Web: www.endo.com
• Phone: (531) 268-2000
• Fax: 800-329-3636
• Employees: 3,103
• Year Founded: 1997

Profitability

• EPS (Most Recent Fiscal Year): ($11.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$613.24 million
• Net Margins: -93.31%
• Pretax Margin: -91.14%
• Return on Equity: -34.25%
• Return on Assets: 6.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.86
• Quick Ratio: 1.62

Sales & Book Value

• Annual Sales: $2.99 billion
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.06
• Book Value: ($13.60) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 235,143,000
• Free Float: 232,321,000
• Market Cap: $141 thousand
• Optionable: No Data
• Beta: 1.15